Key result
High-dose ascorbate reduces medial aortic calcification and preserves aortic structure in mice via Tet2.
Why the study?
Does high-dose ascorbate reduce medial aortic calcification in preclinical models?
Does high-dose ascorbate reduce medial aortic calcification in preclinical models?
Tet2 reactivation via high-dose ascorbate prevents vascular calcification and preserves aortic structure in preclinical models, suggesting a novel therapeutic target.
Vascular calcification arises from the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs) and is a hallmark of many cardiovascular pathologies. This study identifies Tet2, a DNA demethylase, as a critical epigenetic regulator that prevents this phenotypic switch. VSMC-specific loss of Tet2 promotes osteogenic differentiation, apoptosis, increased infiltration of Trem2hi macrophages and medial aortic calcification. High-dose ascorbate used to enhance Tet2 activity significantly reduced calcification and preserved aortic structure in mice. These findings support Tet2 reactivation as a potential therapeutic strategy to prevent or reverse vascular calcification in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied Vascular calcification. High-dose ascorbate was evaluated on Medial aortic calcification. High-dose ascorbate enhanced Tet2 activity, significantly reducing medial aortic calcification and preserving aortic structure in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: